Syndax Pharmaceuticals, Inc. (SNDX) Total liabilities 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) total liabilities at each fiscal year-end, per SEC filings.
$465.1MFY2025 · since FY2016: $24.9M → $465.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $465.1M | +6.5% |
| FY2024 | $436.7M | +644.1% |
| FY2023 | $58.7M | +97.0% |
| FY2022 | $29.8M | -27.9% |
| FY2021 | $41.3M | -14.7% |
| FY2020 | $48.4M | +51.7% |
| FY2019 | $31.9M | +3.3% |
| FY2018 | $30.9M | -6.0% |
| FY2017 | $32.9M | +32.1% |
| FY2016 | $24.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Net marginSNDX Gross profitSNDX Gross marginSNDX Operating incomeSNDX Operating marginSNDX Operating cash flowSNDX Free cash flowSNDX Capital expendituresSNDX Return on equitySNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Shareholders’ equitySNDX overview →